Corbus Pharmaceuticals Holdings (CRBP) Non Operating Investment Income (2022 - 2025)
Corbus Pharmaceuticals Holdings' (CRBP) quarterly Non Operating Investment Income came in at -$58000.0 in Q1 2025, up 82.26% year-on-year from -$31822.6 in Q1 2024, and up 82.26% quarter-over-quarter from -$326949.0 in Q1 2024.
Corbus Pharmaceuticals Holdings (CRBP) Non Operating Investment Income (2022 - 2025) Analysis & Trends
Corbus Pharmaceuticals Holdings' Non Operating Investment Income history runs 4 years deep, the most recent figure standing at -$58000.0 for Q1 2025.
- On a quarterly basis, Non Operating Investment Income rose 82.26% year-over-year to -$58000.0 in Q1 2025; TTM through Mar 2025 was -$362717.0, a 39.49% decrease from a year earlier, with the FY2023 full-year figure at $124536.0, up 295.67% from the prior year.
- Non Operating Investment Income advanced to -$58000.0 in Q1 2025 per CRBP's latest filing, from -$326949.0 in the prior quarter.
- Across five years, Non Operating Investment Income topped out at $80782.0 in Q4 2022 and bottomed at -$326949.0 in Q1 2024.
- The 4-year median for Non Operating Investment Income is $11116.0 (2023), against an average of -$32406.0.
- Across the five-year window, Non Operating Investment Income jumped 153.73% in 2023 and tumbled 667.39% in 2024, its largest moves.
- Year by year, Non Operating Investment Income stood at $80782.0 in 2022, then tumbled by 91.98% to $6479.0 in 2023, then plunged by 5146.29% to -$326949.0 in 2024, then jumped by 82.26% to -$58000.0 in 2025.
- Per Business Quant, the three latest CRBP Non Operating Investment Income figures stand at -$58000.0 (Q1 2025), -$326949.0 (Q1 2024), and $6479.0 (Q4 2023).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Corbus Pharmaceuticals Holdings | 112.73 Mn | 84.92 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | -58,000.00 |
| Mar 31, 2025 | -58,000.00 |
| Mar 31, 2024 | -326,949.00 |
| Mar 31, 2024 | -326,949.00 |
| Dec 31, 2023 | 6,479.00 |
| Dec 31, 2023 | 6,479.00 |
| Sep 30, 2023 | 15,753.00 |
| Sep 30, 2023 | 15,753.00 |
| Jun 30, 2023 | 44,681.00 |
| Jun 30, 2023 | 44,681.00 |
| Mar 31, 2023 | 57,623.00 |
| Mar 31, 2023 | 57,623.00 |
| Dec 31, 2022 | 80,782.00 |
| Dec 31, 2022 | 80,782.00 |
| Sep 30, 2022 | -87,554.00 |
| Sep 30, 2022 | -87,554.00 |
| Jun 30, 2022 | 50,373.00 |
| Jun 30, 2022 | 50,373.00 |
| Mar 31, 2022 | -107,248.00 |
| Mar 31, 2022 | -107,248.00 |